|
Active substance |
Brivaracetam |
|
Holder |
UCB Pharma SA |
|
Status |
Closed |
|
Indication |
Adjunctive treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy |
|
Public documents |
|
|
Last update |
15/09/2020 |
Briviact®
Last updated on 03/04/2024